Situation of the Prescription service

Situation of the Prescription service

The situation of the joint testing of the Prescription service is compiled on this page. Tabulating starts from joint tests completed on 29 April 2016.

Abilita Hälsovård / Abilita Oy Ab

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20102016 / 30.12.2016

Acute / Acuvitec Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20012016 / 30.11.2016

AssisDent / Entteri Professional Software Oy

   Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20062016 / 27.12.2016

DomaCare Medi / Invian Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
Refusal to share prescription information  

1. Ongoing,  20.2.2018
2. Not tested
3. Not tested

 
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20142017 / 14.3.2017

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

DynamicHealth / Tieto Healthcare & Welfare Oy

   Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20032016 / 30.12.2016

Effica / Tieto Healthcare & Welfare Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20032016 / 9.12.2016

Epic / Epic Helsinki Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      

Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information

    20022018 / 5.10.2018

eRA / Atostek Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20092016 / 29.12.2016

ESKO / PPSHP

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20022016 / 9.12.2016

GFS / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     25.11.2016

Hilkka / FastROI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20082016 / 30.12.2016
Refusal to share prescription information     20012018 / 11.1.2018

Kelain / Kela

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20042016 / 9.12.2016
Refusal to share prescription information     20202017 / 1.6.2017

Lifecare /Tieto Healthcare & Welfare Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20192017 / 11.5.2017

MAXX /Receptum Oy 

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20122017 / 11.1.2017
Cross-border prescription     20012019 / 30.9.2019

Mediatri / Mediconsult Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      

Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9

    20072016 / 30.12.2016 
Refusal to share prescription information     20212017 / 5.6.2017

Mediresepti / Mediconsult Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9     20132016 / 30.12.2016
Refusal to share prescription information     20222017 / 4.12.2017 

Navitas / Elisa Appelsiini Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Refusal to share prescription information     20182017 / 24.2.2017

pd3 / Pharmadata Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20172017 / 27.1.2017

Pegasos / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20052016 / 20.12.2016

Salix / Pharmadata Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20162017 / 27.1.2017

SoftMedic / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     22.11.2016

Uranus / CGI Oy

  Registration, return date of pre-test cases Testing phases start date Statement number and date
Ongoing joint testings:       
No ongoing joint testings      
Accepted joint testings:      
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information     20152017 / 11.1.2017 

Last updated 02.10.2019